DAYANG BIOTECH(SZ:003017) Zheng Quan Ri Bao·2025-10-20 22:17Core Viewpoint - The company, Zhejiang Dayang Biotechnology Group Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed, with no false records or significant omissions [1][2][7]. Financial Data - The third-quarter financial report has not been audited [6][7]. - The company confirms that there are no adjustments or restatements required for previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - The company has disclosed information regarding its shareholders, including the total number of ordinary shareholders and the top ten shareholders [4][5]. Other Important Matters - On September 13, 2025, the company announced the completion of the first unlocking period for its employee stock ownership plan, with 60% of the shares eligible for unlocking, amounting to 1,168,218 shares, which represents 1.39% of the total share capital [5]. Board Meeting - The sixth board meeting was held on October 17, 2025, with all nine directors present, and the meeting was conducted in compliance with legal regulations [7][8]. - The board unanimously approved the third-quarter report, affirming that it accurately reflects the company's operational status [8][9].